NASDAQ:TCRX TScan Therapeutics (TCRX) Stock Forecast, Price & News $2.65 0.00 (0.00%) (As of 09/22/2023 ET) Add Compare Share Share Today's Range$2.52▼$2.7050-Day Range$2.04▼$2.9452-Week Range$1.45▼$6.03Volume20,867 shsAverage Volume189,985 shsMarket Capitalization$126.72 millionP/E RatioN/ADividend YieldN/APrice Target$11.50 ProfileProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesSEC FilingsShort InterestSocial MediaProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesSEC FilingsShort InterestSocial Media TScan Therapeutics MarketRank™ ForecastAnalyst RatingBuy3.00 Rating ScoreUpside/Downside334.0% Upside$11.50 Price TargetShort InterestHealthy0.86% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews SentimentN/AInsider TradingN/AProj. Earnings GrowthGrowingFrom ($1.80) to ($1.77) Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.2.20 out of 5 starsMedical Sector447th out of 967 stocksBiological Products, Except Diagnostic Industry64th out of 159 stocks 3.5 Analyst's Opinion Consensus RatingTScan Therapeutics has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 2 buy ratings, no hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $11.50, TScan Therapeutics has a forecasted upside of 334.0% from its current price of $2.65.Amount of Analyst CoverageTScan Therapeutics has only been the subject of 1 research reports in the past 90 days. Previous Next 4.0 Short Interest Percentage of Shares Shorted0.86% of the float of TScan Therapeutics has been sold short.Short Interest Ratio / Days to CoverTScan Therapeutics has a short interest ratio ("days to cover") of 2.5, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in TScan Therapeutics has recently decreased by 4.97%, indicating that investor sentiment is improving. Previous Next 0.0 Dividend Strength Dividend YieldTScan Therapeutics does not currently pay a dividend.Dividend GrowthTScan Therapeutics does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for TCRX. Previous Next 1.1 News and Social Media Coverage Search Interest2 people have searched for TCRX on MarketBeat in the last 30 days. MarketBeat Follows2 people have added TScan Therapeutics to their MarketBeat watchlist in the last 30 days. Previous Next 1.7 Company Ownership Insider Buying vs. Insider SellingIn the past three months, TScan Therapeutics insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 8.27% of the stock of TScan Therapeutics is held by insiders.Percentage Held by Institutions67.73% of the stock of TScan Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 1.3 Earnings and Valuation Earnings GrowthEarnings for TScan Therapeutics are expected to grow in the coming year, from ($1.80) to ($1.77) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of TScan Therapeutics is -0.92, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of TScan Therapeutics is -0.92, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioTScan Therapeutics has a P/B Ratio of 0.65. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here About TScan Therapeutics (NASDAQ:TCRX) StockTScan Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops T cell receptor-engineered T cell therapies for the treatment of patients with cancer. It is developing TSC-100 and TSC-101 that is in Phase I of clinical trial for the treatment of patients with hematologic malignancies to eliminate residual leukemia and prevent relapse after hematopoietic stem cell transplantation; and TSC-204 that is in Phase I for the treatment of solid tumors. The company also developing TSC-200, TSC-201, TSC-202, TSC-203, and TSC-205 for the treatment of solid tumors. In addition, it engages in the developing vaccines for infectious diseases, such as SARS-CoV-2. The company has a collaboration and license agreement with Novartis Institutes for BioMedical Research, Inc., to identify novel cancer antigens from the T cells of patients with a certain specific type of cancer; and a collaboration agreement with Amgen to identify novel targets in Crohn's disease. TScan Therapeutics, Inc. was incorporated in 2018 and is headquartered in Waltham, Massachusetts.Read More TCRX Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart TCRX Stock News HeadlinesSeptember 12, 2023 | finance.yahoo.comSensorium Therapeutics Appoints Veteran Life Sciences Executive Mr. David Southwell to its Board of DirectorsAugust 29, 2023 | finance.yahoo.comTScan Therapeutics Announces FDA Clearance of Investigational New Drug Application for TSC-203-A0201 Targeting PRAMESeptember 23, 2023 | Behind the Markets (Ad)BREAKING: Tiny biotech successfully treats blindnessThere's a tiny biotech in Cambridge that's using a breakthrough technology to treat blindness. This company has already shown success in human trials... And Our research shows that anyone who gets in today could see a 46,751% return.August 16, 2023 | finance.yahoo.comTScan Therapeutics, Inc. (TCRX) Upgraded to Buy: Here's What You Should KnowAugust 11, 2023 | markets.businessinsider.comBarclays Remains a Buy on TScan Therapeutics (TCRX)August 10, 2023 | finance.yahoo.comTScan Therapeutics, Inc. (TCRX) Reports Q2 Loss, Misses Revenue EstimatesJuly 21, 2023 | markets.businessinsider.comAnalysts Have Conflicting Sentiments on These Healthcare Companies: Legend Biotech (LEGN), Gossamer Bio (GOSS) and TScan Therapeutics (TCRX)June 29, 2023 | finanznachrichten.deTScan Therapeutics, Inc.: TScan Therapeutics Announces Transition of Chief Financial OfficerSeptember 23, 2023 | Behind the Markets (Ad)BREAKING: Tiny biotech successfully treats blindnessThere's a tiny biotech in Cambridge that's using a breakthrough technology to treat blindness. This company has already shown success in human trials... And Our research shows that anyone who gets in today could see a 46,751% return.June 29, 2023 | markets.businessinsider.comTScan Therapeutics CFO Brian Silver To Step DownJune 29, 2023 | finance.yahoo.comTScan Therapeutics Announces Transition of Chief Financial OfficerJune 22, 2023 | msn.comWedbush Initiates Coverage of Tscan Therapeutics (TCRX) with Outperform RecommendationJune 15, 2023 | finance.yahoo.comFavourable Signals For TScan Therapeutics: Numerous Insiders Acquired StockJune 15, 2023 | finance.yahoo.comFavourable Signals For TScan Therapeutics: Numerous Insiders Acquired Stock \June 7, 2023 | benzinga.comTScan Therapeutics Insider Trades Send a SignalJune 6, 2023 | finance.yahoo.comTScan Therapeutics Announces FDA Clearance of Investigational New Drug Application for TSC-200-A0201 Targeting HPV16 to Treat Solid TumorsJune 1, 2023 | finance.yahoo.comTScan Therapeutics Announces Closing of Public OfferingJune 1, 2023 | finance.yahoo.comTScan Therapeutics Announces Upcoming Trial in Progress Poster Presentation at the 2023 American Society of Clinical Oncology Annual MeetingJune 1, 2023 | finance.yahoo.comTScan Therapeutics to Participate in the Jefferies Healthcare ConferenceMay 26, 2023 | markets.businessinsider.comTScan Announces Pricing Of Underwritten Public Offering - Quick FactsMay 26, 2023 | msn.comTScan Therapeutics stock slides on pricing $140M securities offeringMay 26, 2023 | finance.yahoo.comTScan Therapeutics Announces Pricing of $140 Million Public OfferingMay 25, 2023 | msn.comTScan Therapeutics plans for stock and warrants offeringMay 25, 2023 | finance.yahoo.comTScan Therapeutics Announces Launch of Proposed Public OfferingMay 24, 2023 | msn.comTScan Therapeutics names Gavin MacBeath permanent CEOMay 24, 2023 | finance.yahoo.comTScan Therapeutics Appoints Gavin MacBeath, Ph.D. as Chief Executive Officer and as a Member of the Board of DirectorsMay 17, 2023 | finance.yahoo.comTScan Therapeutics Shares Fall After Preliminary Data Highlight In Leukemia PatientsSee More Headlines Receive TCRX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for TScan Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address TCRX Company Calendar Last Earnings8/10/2023Today9/23/2023Next Earnings (Estimated)11/08/2023Fiscal Year End12/31/2023Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Biological products, except diagnostic Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:TCRX CUSIPN/A CIK1783328 Webwww.tscan.com Phone857-399-9500FaxN/AEmployees135Year FoundedN/APrice Target and Rating Average Stock Price Forecast$11.50 High Stock Price Forecast$15.00 Low Stock Price Forecast$8.00 Forecasted Upside/Downside+334.0%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage2 Analysts Profitability EPS (Most Recent Fiscal Year)($2.89) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-66,220,000.00 Net Margins-497.11% Pretax Margin-497.11% Return on Equity-67.32% Return on Assets-38.16% Debt Debt-to-Equity Ratio0.16 Current Ratio6.90 Quick Ratio6.90 Sales & Book Value Annual Sales$13.53 million Price / Sales9.37 Cash FlowN/A Price / Cash FlowN/A Book Value$4.10 per share Price / Book0.65Miscellaneous Outstanding Shares47,820,000Free Float43,864,000Market Cap$126.72 million OptionableNot Optionable Beta0.34 Metaverse Stocks And Why You Can't Ignore ThemThinking about investing in Meta, Roblox, or Unity? Click the link to learn what streetwise investors need to know about the metaverse and public markets before making an investment.Get This Free Report Key ExecutivesDr. Gavin MacBeath Ph.D. (Age 53)CEO, Director & Interim Principal Financial Officer Comp: $650.17kDr. Stephen J. Elledge Ph.D.Co-Founder & Chairman of Scientific Advisory BoardMr. Tomasz Kula Ph.D.Co-Founder & Member of Advisory BoardMr. Leiden DworakPrincipal Accounting OfficerMr. Ray LockardSr. VP of Technical Operations & QualityMs. Heather SavelleVP of Investor RelationsDr. Zoran Zdraveski J.D. (Age 53)Ph.D., Chief Legal Officer & Company Sec. Ms. Ann HargravesSr. VP of HRDr. Shrikanta Chattopadhyay M.D.Sr. VP of Medical & Translational MedicineDr. Debora Barton M.D. (Age 47)Chief Medical Officer More ExecutivesKey CompetitorsGraphite BioNASDAQ:GRPHERYTECH PharmaNASDAQ:ERYPOrchard TherapeuticsNASDAQ:ORTXCentury TherapeuticsNASDAQ:IPSCSangamo TherapeuticsNASDAQ:SGMOView All CompetitorsInsiders & InstitutionsBVF Inc. ILBought 2,989,474 shares on 8/15/2023Ownership: 12.338%Stifel Financial CorpBought 99,000 shares on 8/15/2023Ownership: 0.409%State Street CorpBought 14,500 shares on 8/14/2023Ownership: 0.159%Renaissance Technologies LLCBought 135,862 shares on 8/11/2023Ownership: 0.609%Geode Capital Management LLCBought 16,449 shares on 8/11/2023Ownership: 0.482%View All Insider TransactionsView All Institutional Transactions TCRX Stock - Frequently Asked Questions Should I buy or sell TScan Therapeutics stock right now? 2 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for TScan Therapeutics in the last twelve months. There are currently 2 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" TCRX shares. View TCRX analyst ratings or view top-rated stocks. What is TScan Therapeutics' stock price forecast for 2023? 2 equities research analysts have issued twelve-month target prices for TScan Therapeutics' stock. Their TCRX share price forecasts range from $8.00 to $15.00. On average, they expect the company's stock price to reach $11.50 in the next twelve months. This suggests a possible upside of 334.0% from the stock's current price. View analysts price targets for TCRX or view top-rated stocks among Wall Street analysts. How have TCRX shares performed in 2023? TScan Therapeutics' stock was trading at $1.55 at the beginning of 2023. Since then, TCRX stock has increased by 71.0% and is now trading at $2.65. View the best growth stocks for 2023 here. When is TScan Therapeutics' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Wednesday, November 8th 2023. View our TCRX earnings forecast. How were TScan Therapeutics' earnings last quarter? TScan Therapeutics, Inc. (NASDAQ:TCRX) released its quarterly earnings results on Thursday, August, 10th. The company reported ($0.51) earnings per share for the quarter, beating analysts' consensus estimates of ($0.76) by $0.25. The business had revenue of $3.15 million for the quarter, compared to analyst estimates of $3.75 million. TScan Therapeutics had a negative net margin of 497.11% and a negative trailing twelve-month return on equity of 67.32%. What ETF holds TScan Therapeutics' stock ? Simplify Propel Opportunities ETF holds 1,046,916 shares of TCRX stock, representing 2.20% of its portfolio. When did TScan Therapeutics IPO? (TCRX) raised $100 million in an initial public offering on Friday, July 16th 2021. The company issued 6,250,000 shares at a price of $15.00-$17.00 per share. What is TScan Therapeutics' stock symbol? TScan Therapeutics trades on the NASDAQ under the ticker symbol "TCRX." Who are TScan Therapeutics' major shareholders? TScan Therapeutics' stock is owned by many different institutional and retail investors. Top institutional shareholders include BVF Inc. IL (12.34%), BlackRock Inc. (5.21%), Monashee Investment Management LLC (1.65%), Renaissance Technologies LLC (0.61%), Geode Capital Management LLC (0.48%) and Stifel Financial Corp (0.41%). Insiders that own company stock include Brian M Silver, David P Southwell, Gavin Macbeath, Lynx1 Capital Management Lp, Timothy J Barberich and Zoran Zdraveski. View institutional ownership trends. How do I buy shares of TScan Therapeutics? Shares of TCRX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is TScan Therapeutics' stock price today? One share of TCRX stock can currently be purchased for approximately $2.65. How much money does TScan Therapeutics make? TScan Therapeutics (NASDAQ:TCRX) has a market capitalization of $126.72 million and generates $13.53 million in revenue each year. The company earns $-66,220,000.00 in net income (profit) each year or ($2.89) on an earnings per share basis. How many employees does TScan Therapeutics have? The company employs 135 workers across the globe. How can I contact TScan Therapeutics? TScan Therapeutics' mailing address is 830 WINTER STREET, WALTHAM MA, 02451. The official website for the company is www.tscan.com. The company can be reached via phone at 857-399-9500 or via email at tscan@argotpartners.com. This page (NASDAQ:TCRX) was last updated on 9/23/2023 by MarketBeat.com Staff Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding TScan Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.